-
Appointment of Company Secretary
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company’s Financial Controller, was appointed as Company Secretary on 15 January 2021. To download announcement click here
-
ImmuPharma to present at Biotech Showcase™ Digital 2021
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma’s Chief Operating Officer, will be presenting at the prestigious Biotech Showcase™ Digital 2021. The event will be virtually held between 11 and 15 January 2021. As part of ImmuPharma’s participation, an on-demand Company presentation has been provided in advance…
-
Total Share Capital Notification
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company’s Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting…
-
Grant of Share Options & PDMR dealing
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company (“Ordinary Shares”) to Directors, employees and consultants representing 3.8% of ImmuPharma’s Ordinary Shares and total voting rights (the “Options”). ImmuPharma…
-
Conversion of Convertible Security
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Lind Global Macro Fund, LP (“Lind”) has converted $355,112.50 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11…
-
Conversion of Convertible Security
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $200,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on…
-
FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease. The US Food & Drug Administration (“FDA”) has…
-
Total Share Capital Notification
The following replaces the ‘Total Share Capital Notification’ announcement released on 30 September 2020 at 7.01am (BST) under RNS No 5041A. In Section 2 below the reference to “Share Options in whole or part” should have stated 25,640,254 not 15,703,942. 1. Information to be provided for on the basis of Article 15, §1, al.…
-
Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces further regulatory and operational progress for the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”) a potentially life-threatening auto-immune disease. Key highlights: The FDA has offered to accept submission for a Type ‘A’ Meeting Request;…
